Trial Profile
Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisone; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BV mini CHP
- Sponsors Seagen
- 24 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 24 Jun 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
- 10 Sep 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.